NCT02433639View on ClinicalTrials.gov

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Biliary Tract Cancer
Interventions
DRUG

TH-302 monotherapy

TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

Threshold Pharmaceuticals
All Listed Sponsors
collaborator

Threshold Pharmaceuticals

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT02433639 - Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter